サワイグループホールディングス株式会社 · Pharmaceutical · FY ends Mar
| # | Shareholder | Shares | Stake | Value | Dividends |
|---|---|---|---|---|---|
| 1 | 日本マスタートラスト信託銀行株式会社 | 19,880,000 | 17.21% | ¥44.0B | ¥1.1B |
| 2 | 株式会社日本カストディ銀行 | 13,739,000 | 11.89% | ¥30.4B | ¥756M |
| 3 | Mitsuo Sawai | 3,174,000 | 2.74% | ¥7.0B | ¥175M |
| 4 | BNY Mellon as Agent/Clients 10 Percent | 2,975,000 | 2.57% | ¥6.6B | ¥164M |
| 5 | NORTHERN TRUST CO. RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST | 2,940,000 | 2.54% | ¥6.5B | ¥162M |
| 6 | Kenzo Sawai
Asset-management company of Mitsuo Sawai |
2,562,000 | 2.21% | ¥5.7B | ¥141M |
| 7 | 株式会社三井住友銀行 | 1,950,000 | 1.68% | ¥4.3B | ¥107M |
| 8 | Sawai Mitsuro Co., Ltd.
Asset-management company of Mitsuo Sawai |
1,935,000 | 1.67% | ¥4.3B | ¥106M |
| 9 | NORTHERN TRUST CO. RE U.S. TAX EXEMPTED PENSION FUNDS | 1,744,000 | 1.51% | ¥3.9B | ¥95.9M |
| 10 | MSIP Client Securities | 1,662,000 | 1.43% | ¥3.7B | ¥91.4M |
| Name | Title | Shares | Value | Pay |
|---|---|---|---|---|
| Mitsuo Sawai | Chairman, President & Representative Director, CEO, COO | 3,174,000 | ¥7.0B | — |
| 横田 祥士 | Director | 4,000 | ¥8.9M | — |
| 小原 正敏 | Director | 4,000 | ¥8.9M | — |
| 三津 家正之 | Director | — | — | — |
| 相徳 泰子 | Director | — | — | — |
| 坪倉 忠男 | Director (Audit & Supervisory Committee Member) | 3,000 | ¥6.6M | — |
| 谷口 悦子 | Director (Audit & Supervisory Committee Member) | — | — | — |
| Nose Yukiyo | Director (Audit & Supervisory Committee Member) | — | — | — |
Pay is shown only for officers whose pay of ¥100 million or more is disclosed individually.
| Fiscal year | Price | EPS | P/E | Dividend | Shares issued |
|---|---|---|---|---|---|
| FY ending Mar 2026 | ¥2,214 | ¥128.74 | 17.2x | ¥55.0 | 115,487,000 |
| FY ending Mar 2025 | ¥1,983 | ¥90.97 | 21.8x | ¥105.0 | 131,469,000 |
| FY ending Mar 2024 | ¥6,015 | ¥412.01 | 14.6x | ¥130.0 | 43,803,000 |
| FY ending Mar 2023 | ¥3,649 | ¥158.64 | 23.0x | ¥130.0 | 43,791,000 |
| FY ending Mar 2022 | — | ¥-691.14 | — | ¥130.0 | 43,791,000 |